Dipyridamole

CHEMBL932 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

504.6 g/mol

LogP

0.7

Phase

4

A medication that inhibits platelet aggregation and causes vasodilation, used in combination with aspirin to prevent stroke in patients with non-cardioembolic TIA or ischemic stroke, and intravenously as part of cardiac stress testing (pharmacological stress echocardiography or nuclear imaging). It works by inhibiting the phosphodiesterase enzyme that breaks down cyclic AMP. Headache is a very common side effect.

Molekularmasse

504,6000 g/mol

LogP

0,70

TPSA

145,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Cardiovascular Disease Rheumatoid Arthritis Migraine Schizophrenia Systemic Lupus Erythematosus Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1

InChI

InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

Molecular Formula

C24H40N8O4

HBD / HBA

4 / 12

Rotierbare Bindungen

12

Schwere Atome

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A medication that inhibits platelet aggregation and causes vasodilation, used in combination with aspirin to prevent stroke in patients with non-cardioembolic TIA or ischemic stroke, and intravenously as part of cardiac stress testing (pharmacological stress echocardiography or nuclear imaging). It works by inhibiting the phosphodiesterase enzyme that breaks down cyclic AMP. Headache is a very common side effect.

Yes, Dipyridamole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL932. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3108. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Dipyridamole auf PillFYI

Struktur

Schnelldaten

Formel: C24H40N8O4
Synonyme: 2

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.